A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Trial Profile

A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Codrituzumab (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 20 Apr 2016 Results (n = 113)presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 13 Apr 2016 Primary endpoint of progression-free survival has not been met, according to results published in the Journal of Hepatology.
    • 13 Apr 2016 Results published in the Journal of Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top